Health Care [ 8/12 ] | Biotechnology [ 49/73 ]
NASDAQ | Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain.
The company was incorporated in 2022 and is based in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 29, 25 | -0.66 | - |
| May 12, 25 | -1.03 | -1.04 Increased by +0.96% |
| Mar 26, 25 | -3.52 | -0.80 Decreased by -340.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -68.72 M Decreased by -157.09% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -76.59 M Decreased by -285.25% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -52.87 M Decreased by -345.38% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 - | -109.65 M - | Decreased by N/A% - |
| Jun 30, 24 | 0.00 - | -26.73 M - | Decreased by N/A% - |
| Mar 31, 24 | 0.00 - | -19.88 M - | Decreased by N/A% - |
| Dec 31, 23 | 0.00 - | -11.87 M - | Decreased by N/A% - |